Shrs rise as much as 27%, most since May 14, vol. 18% of 3-mo. full-day avg.
- Co. says Sirflox results confirmed meaningful, sees utilization
- Study shows 7.9 month improvement in progress-free survival in liver cancer patients
- NOTE: Prana +19%; European Commission approves PBT2 orphan designation for Huntington’s disease
- 6 buys, 2 holds, 3 sells; avg PT A$27.52: Bloomberg data
Before it's here, it's on the Bloomberg Terminal. LEARN MORE